Needham & Company Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); 2Q11/Early 3Q11 Review - Mipomersen Application in EU (Submitted) and US (Expected by YE11)
Go back to Needham & Company Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); 2Q11/Early 3Q11 Review - Mipomersen Application in EU (Submitted) and US (Expected by YE11)| Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) | Delayed: 57.56 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $57.56 | 52 Week High | $77.80 | |||
| Open | $3.73 | 52 Week Low | $37.38 | |||
| Day High | $57.56 | P/E | N/A | |||
| Day Low | $57.56 | EPS | $-0.35 | |||
| Volume | 15 | |||||
